alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 1.1054-1 Certain stock of Federal National Mortgage Association. ( a ) *In general.* The basis in the hands of the initial holder of a share of stock which is issued pursuant to section 303(c) of the Federal National Mortgage Association Charter Act (12 U.S.C., section 1718) in a taxable year beginning after December 31, 1959, shall be an amount equal to the issuance price of the stock reduced by the amount, if any, required by section 162(d) to be treated (with respect to such share) as an ordinary and necessary business expense. See section 162(d) and § 1.162-19. For purposes of this section the initial holder is the original purchaser who is issued stock of the Federal National Mortgage Association (FNMA) pursuant to section 303(c) of the Act and who appears on the books of FNMA as the initial holder. See § 1.162-19.
( b ) *Example.* The provisions of this section may be illustrated by the following example:
Example: Pursuant to section 303(c) of the Federal National Mortgage Association Charter Act a certificate of FNMA stock is issued to A as of January 1, 1961. The issuance price of the stock was $100 and the fair market value of the stock on the date of issue was $69. A was required by section 162(d) to treat $31 as a business expense for the year 1961. The basis of the share of stock in the hands of A, the initial holder, shall be $69, the amount paid for the stock ($100) reduced by $31.
[T.D. 6690, 28 FR 12254, Nov. 19, 1963]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7726 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7726

To amend chapter 77 of title 5, United States Code, to clarify certain 
due process rights of Federal employees serving in sensitive positions, 
                        and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 19, 2024

Ms. Norton (for herself and Mr. Carson) introduced the following bill; 
  which was referred to the Committee on Oversight and Accountability

_______________________________________________________________________

                                 A BILL

 
To amend chapter 77 of title 5, United States Code, to clarify certain 
due process rights of Federal employees serving in sensitive positions, 
                        and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. AMENDMENTS.

    Section 7701 of title 5, United States Code, is amended--
            (1) by redesignating subsection (k) as subsection (l); and
            (2) by inserting after subsection (j) the following:
    ``(k)(1) An employee or applicant for employment appealing an 
action arising from a determination of ineligibility for a sensitive 
position may not be denied Board review of the merits of such 
determination if--
            ``(A) the position is not one that requires a security 
        clearance or access to classified information; and
            ``(B) such action is otherwise appealable.
    ``(2) For purposes of this subsection, the term `sensitive 
position' means any position so designated pursuant to Executive Order 
10450 (5 U.S.C. 7311 note) or, if superseded, a successor Executive 
order.''.

SEC. 2. EFFECTIVE DATE.

    The amendments made by this Act shall apply to all appeals, without 
exception, that are pending on, or commenced on or after, the date of 
the enactment of this Act.
                                 <all>
```
[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Page 9878]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4697]


-----------------------------------------------------------------------

CONSUMER PRODUCT SAFETY COMMISSION


Sunshine Act Meetings

TIME AND DATE: Wednesday, March 10, 2010; 2 p.m.

PLACE: Hearing Room 420, Bethesda Towers, 4330 East West Highway, 
Bethesda, Maryland.

STATUS: Closed to the Public.

MATTERS TO BE CONSIDERED: 

Compliance Weekly Report--Commission Briefing

    The staff will brief the Commission on the status of various 
compliance matters.
    For a recorded message containing the latest agenda information, 
call (301) 504-7948.

CONTACT PERSON FOR MORE INFORMATION: Todd A. Stevenson, Office of the 
Secretary, U.S. Consumer Product Safety Commission, 4330 East West 
Highway, Bethesda, MD 20814; (301) 504-7923.

    Dated: March 1, 2010.
Todd A. Stevenson,
Secretary.
[FR Doc. 2010-4697 Filed 3-2-10; 4:15 pm]
BILLING CODE 6355-01-P
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.1    
  


Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  


        In connection with the Annual Report on Form 20-F of Swedish Export Credit Corporation (the "Company") for the period ending
December 31, 2001, as amended by Amendment No. 1 filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Peter Yngwe, President of the Company, certify,
pursuant to 18 U.S.C. §1350 as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: 



	(1)
	The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



	(2)
	The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 







	 	 	By:	/s/  PETER YNGWE      
 Peter Yngwe

(President)

April 7, 2003





A signed original of this written statement required by Section 906 has been provided to Swedish Export Credit Corporation and will be retained by Swedish Export Credit
Corporation and furnished to the Securities and Exchange Commission or its staff upon request.





 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  



        In connection with the Annual Report on Form 20-F of Swedish Export Credit Corporation (the "Company") for the period ending
December 31, 2001, as amended by Amendment No. 1 filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jakob Nordin, Executive Director, Financial
Control, of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: 



	(1)
	The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



	(2)
	The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 







	 	 	By:	/s/  JAKOB NORDIN      
 Jakob Nordin

(Executive Director, Financial Control)

April 7, 2003





A signed original of this written statement required by Section 906 has been provided to Swedish Export Credit Corporation and will be retained by Swedish Export Credit
Corporation and furnished to the Securities and Exchange Commission or its staff upon request.


2









QuickLinks



EXHIBIT 10.1
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.3920 Aqueous shunt. ( a ) *Identification.* An aqueous shunt is an implantable device intended to reduce intraocular pressure in the anterior chamber of the eye in patients with neovascular glaucoma or with glaucoma when medical and conventional surgical treatments have failed.
( b ) *Classification.* Class II. The special controls for this device are FDA's: ( 1 ) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Devices—Part I: Evaluation and Testing,’ ”
( 2 ) “510(k) Sterility Review Guidance of 2/12/90 (K90-1),” and
( 3 ) “Aqueous Shunts—510(k) Submissions.”
[65 FR 17147, Mar. 31, 2000, as amended at 66 FR 18542, Apr. 10, 2001]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4550 Autofluorescence detection device for general surgery and dermatological use. ( a ) *Identification.* An autofluorescence detection device for general surgery and dermatological use is an adjunct tool that uses autofluorescence to detect tissues or structures. This device is not intended to provide a diagnosis.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) In vivo testing under anticipated conditions of use must characterize the ability of the device to detect autofluorescent signals from tissues or structures consistent with the indications for use.
( 2 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 3 ) Performance testing must demonstrate the electromagnetic compatibility and electrical, mechanical, and thermal safety of the device.
( 4 ) Software verification, validation, and hazard analysis must be performed.
( 5 ) Performance testing must demonstrate the sterility of patient-contacting components of the device.
( 6 ) Performance testing must support the shelf life of device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life.
( 7 ) Performance testing must demonstrate laser and light safety for eye, tissue, and skin.
( 8 ) Labeling must include the following: ( i ) Instructions for use;
( ii ) The detection performance characteristics of the device when used as intended; and
( iii ) A shelf life for any sterile components.
[87 FR 24273, Apr. 25, 2022]
Exhibit 35.1



AMERICAN HONDA FINANCE CORPORATION

ANNUAL COMPLIANCE CERTIFICATE

PURSUANT TO SECTION 3.11(a) OF THE

SALE AND SERVICING AGREEMENT AND

ITEM 1123 OF REGULATION AB



I, Paul C. Honda, do
hereby certify that I am the Vice President and Assistant Secretary of American Honda Finance Corporation, a California corporation
(the “Company”), and further certify on behalf of the Company in its capacity as servicer (the “Servicer”
and “Sponsor”) under the Sale and Servicing Agreement (the “Agreement”) dated as of August 19, 2015 among
the Servicer and Sponsor, American Honda Receivables LLC, as Seller, and Honda Auto Receivables 2015-3 Owner Trust, as follows:



| | (i) | A review of the activities of the Servicer during the reporting period ended March 31, 2016, and
of its performance under the Agreement has been made under my supervision.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (ii) | To the best of my knowledge, based on such review, the Servicer has fulfilled all of its obligations
under the Agreement throughout such period in all material respects.
| | ---- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------



IN WITNESS WHEREOF, I have hereunto set
my hand this 16th day of May, 2016.



| | /s/ Paul C. Honda                                   
| | ----------------------------------------------------
| | Paul C. Honda                                       
| | Vice President and Assistant Secretary              
| | (senior officer in charge of the servicing function)
<TABLE> <S> <C>


<ARTICLE>                     5
<MULTIPLIER>                          1000

<S>                            <C>
<PERIOD-TYPE>                  3-MOS
<FISCAL-YEAR-END>              DEC-30-2000
<PERIOD-START>                 JAN-02-2000
<PERIOD-END>                   APR-01-2000
<CASH>                               15100
<SECURITIES>                         32300
<RECEIVABLES>                        48200
<ALLOWANCES>                          2400
<INVENTORY>                         369400
<CURRENT-ASSETS>                    498800
<PP&E>                              360000
<DEPRECIATION>                      119700
<TOTAL-ASSETS>                      783600
<CURRENT-LIABILITIES>               385100
<BONDS>                                  0
<COMMON>                               300
<PREFERRED-MANDATORY>                    0
<PREFERRED>                              0
<OTHER-SE>                          259500
<TOTAL-LIABILITY-AND-EQUITY>        783600
<SALES>                             439700
<TOTAL-REVENUES>                    439700
<CGS>                               312700
<TOTAL-COSTS>                       312700
<OTHER-EXPENSES>                    116500
<LOSS-PROVISION>                         0
<INTEREST-EXPENSE>                     500
<INCOME-PRETAX>                      10000
<INCOME-TAX>                          3100
<INCOME-CONTINUING>                   2800
<DISCONTINUED>                           0
<EXTRAORDINARY>                          0
<CHANGES>                                0
<NET-INCOME>                           2800
<EPS-BASIC>                            0.14
<EPS-DILUTED>                          0.14



</TABLE>
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1410 Nuclear electrocardiograph synchronizer. ( a ) *Identification.* A nuclear electrocardiograph synchronizer is a device intended for use in nuclear radiology to relate the time of image formation to the cardiac cycle during the production of dynamic cardiac images.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 892.9.
[55 FR 48444, Nov. 20, 1990, as amended at 65 FR 2322, Jan. 14, 2000]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.4700 Automated fluorescence *in situ* hybridization (FISH) enumeration systems. ( a ) *Identification.* An automated FISH enumeration system is a device that consists of an automated scanning microscope, image analysis system, and customized software applications for FISH assays. This device is intended for in vitro diagnostic use with FISH assays as an aid in the detection, counting and classification of cells based on recognition of cellular color, size, and shape, and in the detection and enumeration of FISH signals in interphase nuclei of formalin-fixed, paraffin-embedded human tissue specimens.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Automated Fluorescence *in situ* Hybridization (FISH) Enumeration Systems.” See § 866.1(e) for the availability of this guidance document.
[70 FR 14534, Mar. 23, 2005]
| (logo) WELLS FARGO | **Commercial Mortgage  Servicing**D1050-084, 8th Floor  401 South Tryon St.  Charlotte, NC 28202  1-800-326-1334 |
|--------------------|------------------------------------------------------------------------------------------------------------------|

 

 

**ANNUAL STATEMENT OFCOMPLIANCE**

 

Reference is hereby made tothat certain Pooling and Servicing Agreement dated as of August 1, 2015, by andamong WELLS FARGO COMMERCIAL MORTGAGE SECURITIES, INC., as Depositor, WELLSFARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, RIALTO CAPITAL ADVISORS,LLC, as Special Servicer, TRIMONT REAL ESTATE ADVISORS, INC, as Trust Advisor,WELLS FARGO BANK, NATIONAL ASSOCIATION, as Certificate Administrator, as Tax Administratorand as Custodian and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee, withrespect to Commercial Mortgage Pass-Through Certificates Series 2015-SG1(the"Agreement"). Capitalized terms used herein not otherwise definedshall have the meanings assigned in the Agreement. 

 

Pursuant to Section 11.12 ofthis Agreement, I, Daniel Bober, Executive Vice President of CommercialMortgage Services do hereby certify that: 1. 

 

A review of the activities ofthe Master Servicer during the period from January 1, 2016 through December 31,2016 (the “Reporting Period”), and of its performance per the Agreement duringsuch period has been made under my supervision, and 

 

2. To the best of myknowledge, based on such review, the Master Servicer, has fulfilled all of itsobligations under this Agreement in all material respects throughout theReporting Period. 

 

IN WITNESS WHEREOF, theundersigned has executed this Certificate as of the 28th day of February 2017.

 

/s/ Daniel Bober

Daniel Bober

Executive Vice President 

Wells Fargo Bank

 

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll go far |
|------------------------|------------------------------------|
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                         536,000
<SECURITIES>                                         0
<RECEIVABLES>                                1,841,000
<ALLOWANCES>                                   144,000
<INVENTORY>                                  3,169,000
<CURRENT-ASSETS>                             5,818,000
<PP&E>                                       4,701,000
<DEPRECIATION>                               1,051,000
<TOTAL-ASSETS>                              12,145,000
<CURRENT-LIABILITIES>                        4,447,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    21,290,000
<OTHER-SE>                                     177,000
<TOTAL-LIABILITY-AND-EQUITY>                12,145,000
<SALES>                                              0
<TOTAL-REVENUES>                             1,292,000
<CGS>                                                0
<TOTAL-COSTS>                                  942,000
<OTHER-EXPENSES>                             1,253,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             (34,000)
<INCOME-PRETAX>                               (954,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (954,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (954,000)
<EPS-PRIMARY>                                    (.15)
<EPS-DILUTED>                                    (.15)
        

</TABLE>
Addendum to Factoring Agreement with Pacific Business Funding



 
EXHIBIT 10.39

 
[PACIFIC BUSINESS FUNDING LOGO] 
 
June 28, 2002 
 
Michael Perez 
Chief Financial Officer 
Lexar Media, Inc. 
47421 Bayside Pkwy 
Fremont, CA 94538 
 
RE: Addendum to the Factoring Agreement (“Agreement”) dated
September 12, 2001 
 
Dear Michael: 
 
As of June 28, 2002, Pacific Business Funding, a division of Cupertino
National Bank (“PBF” or “Bank”) and a member of the Greater Bay Bancorp (NASDAQ: GBBK) has agreed to new following changes to the original Factoring Agreement (“Agreement”) dated and signed on September 12, 2001
between PBF and Lexar Media, Inc. (“Borrower”). Besides the new terms clearly stated below, all the rights granted to each party in the Factoring Agreement (“Agreement”) shall remain completely unchanged. The approved
changes are as follows: 
 

	•	 	Increase the maximum loan amount from $10,000,000.00 to $15,000,000.00. 

 

	•	 	Decrease the interest rate to the Bank’s Prime Rate plus 4.5%. 

 

	•	 	Eliminate the administration fee. 

 

	•	 	The facility will mature on July 5, 2003. 

 
Mike, the entire PBF and myself have truly enjoyed working with you and your team this past year. We are pleased to present the above terms to you. As
always, should you need anything else of have any questions on the above, please do not hesitate to call. 
 
Regards, 
 
/s/    Mike Hansen 
 
Mike
Hansen 
Vice President 
 
Acknowledged: 
 

	
	 BY:
	 	 /s/    Michael
Perez        


	
	 IT’S:
	 	 CFO, VP FINANCE


	
	 DATE:
	 	 7/1/02



 
A
DIVISION OF CUPERTINO NATIONAL BANK 
 
A MEMBER OF THE GREATER BAY BANCORP FAMILY 
 

20195
STEVENS CREEK BLVD.    •    SUITE #220    •    CUPERTINO, CA 95014    •    TEL: 408
255-9300    •    FAX: 408 255-9313 
WWW. PBFC. COM
[Federal Register Volume 75, Number 8 (Wednesday, January 13, 2010)]
[Notices]
[Page 1749]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-513]


-----------------------------------------------------------------------

DEPARTMENT OF AGRICULTURE

Forest Service


Eastern Washington Cascades Provincial Advisory Committee and the 
Yakima Provincial Advisory Committee

AGENCY: Forest Service, USDA.

ACTION: Notice of Meeting.

-----------------------------------------------------------------------

SUMMARY: The Eastern Washington Cascades Provincial Advisory Committee 
and the Yakima Provincial Advisory Committee will meet on February 3, 
2010 at the Okanogan-Wenatchee National Forest Headquarters office, 215 
Melody Lane, Wenatchee, WA. During this meeting information will be 
shared about Holden Mine clean-up operations, Stehekin River Corridor 
Implementation Plan/Environmental Impact Statement, and Bureau of Land 
Management Resource Management Plan update. All Eastern Washington 
Cascades and Yakima Province Advisory Committee meetings are open to 
the public.

FOR FURTHER INFORMATION CONTACT: Direct questions regarding this 
meeting to Becki Heath, Designated Federal Official, USDA, Okanogan-
Wenatchee National Forest, 215 Melody Lane, Wenatchee, Washington 
98801, phone 509-664-9200.

    Dated: January 6, 2010.
Rebecca Lockett Heath,
Designated Federal Official, Okanogan-Wenatchee National Forest.
[FR Doc. 2010-513 Filed 1-12-10; 8:45 am]
BILLING CODE 3410-11-P
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Stephen J. Markman

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

Richard H. Bernstein

Joan L. Larsen,

Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

November 6, 2015

d1103 

# Order

Clerk November 6, 2015

152208

- 9(40)

SC: 152208

- 9

In re MOTTWEILER, Minors. COA: 325278; 325279

Cass CC Family Division:

13

- 000086

- NA

_______________________________________/

On order of the Court, the motion for reconsideration of this Court’s September

30, 2015 order is considered, and it is DENIED, because it does not appear that the order

was entered erroneously.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5150 Anesthesia conduction needle. ( a ) *Identification.* An anesthesia conduction needle is a device used to inject local anesthetics into a patient to provide regional anesthesia.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.3250 Vascular clip. ( a ) *Identification.* A vascular clip is an implanted extravascular device designed to occlude, by compression, blood flow in small blood vessels other than intracranial vessels.
( b ) *Classification.* Class II (performance standards).
# Funding & Grants

Listen
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1680 Ophthalmic projector. ( a ) *Identification.* An ophthalmic projector is an AC-powered device intended to project an image on a screen for vision testing.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9.
[55 FR 48442, Nov. 20, 1990, as amended at 59 FR 63013, Dec. 7, 1994; 66 FR 38812, July 25, 2001]